Potentiating pneumococcal glycoconjugate vaccine pcv13 with saponin adjuvant vsa-1

HIGHLIGHTS

  • who: Hyunjung Kim from the Army Medical University, China have published the research work: Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1, in the Journal: (JOURNAL)
  • what: The authors report the results of comparing VSA-1 and QS-21 in enhancing the immune_responses induced by the clinical glycoconjugate pneumococcal vaccine PCV13.

SUMMARY

    There are two types of clinical pneumococcal vaccines: pneumococcal polysaccharide vaccine (e_g, PPV23, composed of purified pneumococcal capsular polysaccharides (CPS) of 23 serotypes of S. pneumoniae) and pneumococcal glycoconjugate vaccine (e_g, PCV13, composed of purified CPS of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?